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Introduction
Thrombotic thrombocytopenic purpura (TTP), 
a disease characterised by disseminated thrombotic 
microangiopathy associated with haemolytic 
microangiopathic anaemia, was described for the first 
time by Eli Moscowitz in 1925 as an "acute febrile 
pleiochromic anaemia with hyaline thrombosis of 
the terminal arterioles and capillaries"1. The disease 
is now better understood from a pathophysiological 
point of view even though its rarity (annual incidence 
of 11.3 cases per 1,000,000 population)2 and the 
lack of specificity of the signs, symptoms and 
laboratory findings make its management difficult. 
The symptoms, as stated, are non-specific: fever, 
renal dysfunction (to the point of acute renal failure in 
some cases), fluctuating neurological disorders (mild 
headache, onset of behavioural anomalies, transient 
sensory and motor deficits, coma), possible ischaemic 
gastrointestinal complications (abdominal pain) and 
retinal detachment. More than 35% of patients do not 
have neurological symptoms at onset; fever and renal 
dysfunction are present in only a small minority of 
cases. The diagnosis can, therefore, be made in the 
presence of a microangiopathic haemolytic anaemia 
(with schistocytes in a peripheral blood smear), 
thrombocytopenia (from platelet consumption) and 
increased levels of lactate dehydrogenase (LDH) not 
due to other identifiable causes3,4.
In 1982, as a result of the need to aid the differential 
diagnosis in these cases, Moake et al.5 observed that 
the pathogenesis of TTP is closely related to von 
Willebrand factor (VWF) since there were unusually 
large or ultralarge multimers of VWF (ULVWF) in 
the circulation of patients with TTP whereas these 
multimers were not present in patients in remission 
or in healthy controls. Moake hypothesised that 
the patients with TTP lacked a protease capable 
of cleaving the ULVWF multimers to prevent the 
intravascular formation of thrombi. Only in 1996, 
drawing on the independent observations of Tsai6 
and Furlan7, there was an understanding of the 
relationship with a metalloprotease whose lack or 
inhibition plays a key role in the pathology of TTP8,9: 
ADAMTS 13, "a disintegrin-like and metalloprotease 
with thrombospondin repeats".
In conditions of high shear stress in the blood, the 
ULVWF multimers secreted by activated endothelial 
cells are anchored as filaments to the molecules of 
P-selectin exposed on the surface of the activated 
endothelium. ADAMTS13 regulates the length and, 
therefore, the thrombogenic potential of the VWF by 
binding to the accessible A3 domains of the VWF and 
breaking down the ULVWF multimers by cleaving the 
peptide bond between the Tyr1605-Met1606 residues 
in the A2 domain. As a consequence of a lack of 
ADAMTS13 (activity ≤50%), ULVWF multimers are 
not broken down after being secreted by endothelial 
cells, but remain anchored to the endothelium. 
Platelets passing close by adhere through GpIb and 
the GpIIb/IIIa complex to the A1 and A3 domains 
of the monomeric subunits of the ULVWF filaments 
anchored to the P-selectin and form large, occlusive 
thrombi.
In congenital forms of TTP mutations have been 
found in the gene for ADAMTS 13 (located on 
chromosome 9q34). More than 70 mutations have 
been identified so far: 60% are missense mutations, 
while the other 40% are nonsense, frameshift or 
splicing mutations10,11. The disease has an autosomal 
recessive mode of inheritance and is usually, but 
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not always, manifested at birth or during infancy. 
The congenital cases are extremely rare (incidence 
1:1,000,000) and account for a small percentage 
(5%) of all cases of TTP. More frequently the 
disease is manifested in adults as secondary TTP 
(in haematopoietic stem cell transplant recipients, 
in pregnant women, in patients with autoimmune 
diseases, human immunodeficiency virus infection 
or cancer12) or as idiopathic TTP characterised in 
70-80% of cases by the presence of IgG autoantibodies 
(mainly IgG4) capable of inhibiting the enzymatic 
function of ADAMTS13 in various ways. IgG4 block 
the proteolytic activity of ADAMTS13 with regards 
to VWF, increasing the clearance of ADAMTS13 
from the bloodstream, or can interfere with the 
interactions between ADAMTS13 and cells or other 
plasma proteins. The biological function of the IgG 
is strongly dependent on their specificity, affinity and 
subclass: IgG4 are produced mainly after a prolonged 
period of antigenic stimulation and for this reason 
the abundant production of IgG4 anti-ADAMTS13 
autoantibodies suggests a condition of chronic 
antigenic stimulation of the immune system when 
the mechanisms of systemic immune tolerance fail14. 
From a transfusional point of view, the interest in 
TTP is based on the possibility of treating patients with 
plasma exchange (PEX) with fresh-frozen plasma. 
Since the introduction of this treatment in the 1970s, 
the natural history of TTP has changed radically, with 
70-80% of patients obtaining a complete remission 
(compared to a mortality rate of 90% in untreated 
patients)12. The problem with the treatment of TTP is 
that although 80% of patients have a complete response 
to therapy (responders), about 20% of patients relapse 
after successful treatment of an acute episode or are 
refractory to PEX with persistent thrombocytopenia 
and high levels of LDH after a complete cycle of 
treatment (at least 7 days) of PEX (refractory or 
non-responders or partial responders). The Canadian 
Apheresis group found that 36% of patients with TTP 
relapsed during a 10-year follow-up2,4,13.
Our experience
In a 2-month period (May - July 2011) the therapeutic 
apheresis group at the Service of Transfusion Medicine 
of "Paolo Giaccone" Hospital in Palermo observed and 
used PEX to treat four cases of acquired TTP attending 
the Haematology Unit of the same hospital.
After a careful clinical evaluation, the diagnosis of 
TTP was made on the basis of signs of microangiopathic 
haemolysis, a negative Coombs' test, decreases in 
haemoglobin concentration and platelet count, an 
increase in the number of reticulocytes, the presence of 
schistocytes in a peripheral blood smear, and increases 
in the values of total bilirubin and serum activity of 
LDH. The diagnosis was not, however, supported 
by the search for anti-ADAMTS13 antibodies or an 
evaluation of the activity of this enzyme. 
All the patients were treated with the same 
therapeutic regimen which, in accordance with the 
guidelines from the American Society for Apheresis15, 
consisted of daily PEX with the exchange of at least 
one plasma volume. The replacement fluid, which 
was fresh-frozen plasma and physiological saline in 
a ratio of 2:1, enabled 100% of the plasma volume 
to be exchanged in all four patients. At least nine 
exchange sessions were performed before achieving 
a normal platelet count (≥150x109/L) and LDH levels 
(≤300 IU/L) on 3 consecutive days. Furthermore, 
each patient was treated with adjuvant corticosteroids 
(methylprednisolone 1 mg/Kg/die)4,15. The transfusion 
therapy consisted of infusion of red cell concentrates 
and platelets to enable the placement of a central venous 
catheter without running the risk of haemorrhage 
during its insertion. After normalisation of the platelet 
count, the PEX was suspended for clinical observation 
and laboratory studies. The patients were discharged 
only after their platelet counts and LDH levels had 
remained stable for 1 week (Table I).
The observation of so many patients in such a short 
time stimulated our group to evaluate the patients' 
response to treatment, in terms of normalisation 
of platelet count, levels of LDH and haemoglobin 
concentration, during and immediately after the PEX 
therapy. 
Case 1
A 29-year old secundipara (blood group O 
positive, phenotype Rh CCDee, kk) was referred to 
us because of a first relapse of TTP. The diagnosis 
had been made 18 months earlier during the woman's 
second pregnancy (38th week), when she was admitted 
to hospital because of anaemia and worsening 
thrombocytopenia with diffuse petechiae on the 
abdomen and lower limbs. On that occasion, treatment 
was started with steroids and an infusion of fresh-
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frozen plasma: the woman had a complete response 
which enabled her pregnancy to be concluded with a 
delivery by Caesarean section. Following discharge 
from hospital, the patient had monthly follow-up 
assessments for 6 months with apparent resolution of 
the disease. The relapse started with a fever (lasting 
1 week) with considerable weakness followed by 
the appearance of petechiae on the lower limbs and 
pathognomonic laboratory evidence of recurrent 
disease (platelet count 5x109/L, Hb 8.3 g/dL) together 
with increased indices of haemolysis and renal 
function (total bilirubin 3.91 mg/dL, LDH 3669 
IU/L, AST/ALT 48/31 IU/L, creatinine 1.7 mg/dL), 
a negative Coombs' test and six to seven schistocytes 
per field in a peripheral blood smear. 
A therapeutic protocol of PEX was started 
immediately and, in relation to her own plasma 
volume, the patient's plasma was exchanged with 
2,000 mL of fresh-frozen plasma/die (percentage of 
plasma volume exchanged: 100%) for 9 days until her 
platelet count and haemoglobin concentration reached 
levels compatible with resolution of the dyscrasia and 
haemolysis (platelets ≥140x109/L, Hb ≥10 g/dL, total 
and direct bilirubin ≤1mg/dL). 
Eight days after suspension of PEX the disease 
Table I - Clinical and laboratory features of the four patients with TTP.
Case 1 Case 2 Case 3 Case 4
Age (years) 29 50 54 31
Type of TTP Relapsed TTP Acute TTP Acute TTP Post-partum TTP 
Blood group O CCDee A CcDEe A CcDEe A CcDEe
Disease onset Anaemia, 
thrombocytopenia and 
petechiae of lower limbs
Anaemia, 
thrombocytopenia
and meno-metrorragia
Anaemia, 
thrombocytopenia and 
petechiae of  lower limbs
Anaemia, 
thrombocytopenia
and paraesthesia
Laboratory parameters
at onset
Hb 8.3 g/dL; Plt 5x109/L; 
LDH 3669 IU/L
Hb 8.4 g/dL; Plt 20x109/L; 
LDH 2180 IU/L
Hb 7.4g/dL; Plt 23x109/L; 
LDH 1274 IU/L
Hb 9 g/dL; Plt 28x109/L; 
LDH 1588 IU/L
PEX 9 exchange sessions 
(2,000 mL plasmasafe)
10 exchange sessions 
(2,200 mL plasmasafe)
9 exchange sessions 
(2,000 mL plasmasafe)
11 exchange sessions 
(2,200 mL plasmasafe)
Plasma volume exchanged 
(%) 100% 100% 100% 100%
Transfusion treatment 4 units of RBC, 23 units 
of FFP, 2 units of Plt 
from apheresis
2 units of RBC, 20 units 
of FFP, 1 unit of Plt 
from apheresis  
1 unit of RBC,
27 units of FFP 
2 units of RBC, 16 units 
of FFP, 2 units of Plt 
from apheresis 
Adjuvant treatment methylprednisolone methylprednisolone methylprednisolone methylprednisolone
Start of rituximab 
treatment 
(day of admission)
day 26 day 17 no no
Laboratory parameters
at discharge
Hb 10.5 g/dL; 
Plt 92x109/L; 
LDH 475 IU/L
Hb 10 g/dL; 
Plt 163x109/L; 
LDH 440 IU/L
Hb 11.1 g/dL; 
Plt 183x109/L; 
LDH 279 IU/L
Hb 11.4 g/dL; 
Plt 122x109/L; 
LDH 241 IU/L
recurred with a new decrease in the platelet count 
(platelets 52x109/L), so the patient was treated with 
rituximab 600 mg (Figure 1). 
Case 2
A 50-year old woman (blood group A Rh positive, 
phenotype CcDEe Kk) with a euthyroid nodular 
goitre in menopause for 1 year was referred to 
us because of progressive weakness, ecchymoses 
and an episode of marked meno-metrorrhagia. 
Laboratory tests showed anaemia (Hb 9.5 g/dL), 
thrombocytopenia (platelets 20x109/L) and indices 
of haemolysis (LDH 2,180 IU/L, total bilirubin 3.36 
g/dL), five to six schistocytes per field in a peripheral 
blood smear and a negative Coombs' test compatible 
with the diagnosis of TTP. The patient had no 
neurolological disorders or neuropsychological 
alterations.
The patient started treatment with PEX, in 
which her plasma was exchanged with 2,200 mL 
of fresh-frozen plasma/die (percentage of plasma 
volume exchanged: 100%) in ten sessions at the 
end of which she had a good recovery of her blood 
count and normalisation of indices of haemolysis. 
After the sixth session of plasmapheresis the patient 
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suddenly developed fever (39 °C), high levels of 
transaminases (ALT 224 IU/L) and a new decrease 
in platelet count, so she was started on treatment with 
rituximab 600 mg. After a few hours high levels of 
transaminases associated with a fever were again 
recorded levels and for this reason the treatment 
was suspended. Only 6 days later was reactivation 
of a previous cytomegalovirus (CMV) infection 
clearly demonstrated (CMV IgM negative, CMV 
IgG positive, CMV pp65 positive, CMV DNA 
positive) and specific antiviral treatment was started 
(valaciclovir hydrocholoride) (Figure 2).
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Figure 2 - Trends in platelet count (Plt) and transaminase concentration (ALT) 
from the day of admission and in relation to the plasma exchange 
sessions (arrows) in a patient with cytomegalovirus infection.
Figure 1 - First relapse of TTP: trend in platelet count (Plt), haemoglobin 
concentration (Hb) and levels of total bilirubin (Bil Tot) and lactate 
dehydrogenase (LDH) during treatment with plasma exchange 
(box): the lack of a platelet response is clear.
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Case 3
The third case was a 54-year old woman (blood 
group A Rh positive CcDEe kk) with an approximately 
20-year history of Raynaud's phenomenon for which she 
is regularly treated in the Day Hospital with iloprost, a 
synthetic analogue of prostacyclin I with vasodilating, 
antioxidant and anti-aggregant activity. During the 
woman's last planned admission to the angiology ward, 
in which she should have received her treatment and 
follow-up, she was seen to have evident manifestations 
of cutaneous bleeding (petechiae on the lower limbs, 
ecchymoses in the gluteal region, haematuria) with 
clear laboratory evidence of anaemia (Hb 7.4 g/dL), 
thrombocytopenia (platelets 23x 109/L) and haemolysis 
(total bilirubin 1.39 g/dL; LDH 1,274 IU/L). There 
were six to seven schistocytes per field in the peripheral 
blood smear. The Coombs' test was negative. These 
findings were immediately compatible with a diagnosis 
of TTP, despite the absence of neurological disorders or 
neuropsychological disturbances, and PEX treatment 
was started with the aim of exchanging the patient's 
plasma with 2,000 mL of fresh-frozen plasma/die 
(percentage of plasma volume exchanged: 100%). At 
the end of the cycle of nine sessions, the patient had a 
good blood count recovery and complete resolution of 
haemolysis (Hb 11.1 g/dL; platelets 183x109/L; LDH 
279 IU/L) (Figure 3). 
Case 4
A 31-year old pluripara (blood group A Rh 
positive with phenotype CcDEe kk) was referred 
to us because 1 month after her last delivery she 
developed notable weakness with even modest 
efforts often associated with recurrent paraesthesia 
of the upper limbs. At the time of her admission the 
clinical findings and laboratory results -anaemia 
(Hb 9 g/dL), thrombocytopenia (platelets 28x109/L), 
signs of haemolysis (total bilirubin 2.13 g/dL; LDH 
1,588 IU/L)- together with the presence of three to 
four schistocytes per field in a peripheral blood smear 
suggested a diagnosis of post-partum TTP. The patient 
was treated with 11 sessions of PEX in which her 
plasma was exchanged with 2,000 mL of fresh-frozen 
plasma/die (percentage of plasma volume exchanged: 
100%); she was also given adjuvant cortisone therapy. 
During the first sessions of PEX the woman had an 
evident neurological disorder (dysarthria) which 
resolved completely as treatment was continued.
At the end of the treatment the patient had a clear 
recovery of platelet count (platelets 154x109/L), 
an improvement of the picture of haemolysis (total 
bilirubin 0.30 g/dL; LDH 230 IU/L) and resolution 
of anaemia (Hb 11 g/dL) (Figure 4).
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Figure 3 - Trends in indices of haemolysis, thrombocytopenia 
and anaemia in a patient with Raynaud's 
phenomenon who responded to treatment with 
plasma exchange (sessions of plasma exchange 
carried out on the days shown in the box).
Figure 4 - Trends in laboratory parameters in a patient with 
post-partum TTP who responded to treatment 
with plasma exchange.
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Discussion
The cases observed highlighted some particularly 
interesting clinical aspects. During a careful evaluation 
of the pharmacological history of case 1, it emerged that 
2 months prior to the onset of the relapse, the patient had 
spontaneously assumed dietary supplements containing 
chitosan, a non-acetylated or partially deacetylated linear 
polysaccharide derived from chitin (which is found in 
nature in the exoskeleton of crustaceans, in the cuticle 
of insects and in the cell walls of fungi) associated with 
succinic acid16. Although a strong relationship between 
these molecules and the appearance of TTP has not been 
described in the literature, it is known that chitosan acts 
in vitro as a modulator of the activation and adhesion of 
platelets such that already a few years ago its haemostatic 
effect in heparinised mice was noted, confirming the fact 
that its activity does not depend on the interference with 
the coagulation cascade, but rather from an interaction 
with the elements of primary haemostasis17. Subsequent 
studies demonstrated that chitosan-dependent platelet 
activation causes the release of growth factors contained 
in the α-granules of platelets and this stimulus could, 
therefore, be potentially useful for activating platelet-
rich plasma, by-passing the allergic and prothrombotic 
effects of the thrombin normally used for this purpose18. 
In addition, a recent study indicated that succinate 
could also be an independent platelet activator19. It can, 
therefore, be hypothesised that, in the presence of a 
pathological condition predisposing to the formation 
of thrombi, a stimulus of this type could trigger relapse 
of the disease.
Case 2, in contrast, showed an interesting 
association between TTP and CMV infection. As 
recently observed20 there may be relationship (albeit 
not well defined) between infections (including 
those by CMV) and TTP, particularly as regards 
response to therapy and the possibility of relapses 
or exacerbations. The mechanism of action of this 
is unclear but it is possible that infections together 
with other inflammatory stimuli could alter the 
delicate equilibrium between VWF and the activity 
of ADAMTS13. Infection-induced vascular activation 
could increase the release of ULVWF through the 
effects of interleukin-8 and tumour necrosis factor-α, 
while interleukin-6 inhibits the cleavage of ULVWF21; 
on the other hand, sepsis causes a decrease in the 
activity of ADAMTS13 both through its cleavage by 
proteolytic enzymes in the bloodstream and through 
its reduced synthesis in the liver22. Furthermore, it 
is possible that, as for other micro-organisms, the 
immunogenic stimulation of the infection could cause 
a cross-reaction with anti-ADAMTS13 antibodies, 
reducing the activity of the protein and thereby 
limiting the response to therapy21,23. Furthermore, 
in the specific case of CMV, this virus can infect 
megakaryocytes directly and, therefore, reduce the 
production of platelets24. Indeed, we observed a 
proportional, inverse relationship between platelet 
count and transaminase levels in our patient (Figure 2). 
As far as concerns case 3, Raynaud's phenomenon, 
the clinical expression of a transitory ischaemic crisis 
caused by vasoconstriction of the digital arteries, 
precapillary arterioles and cutaneous arteriovenous 
shunts in response to cold or emotion, can present as a 
primary condition or secondary to systemic sclerosis. 
The pathogenesis of this phenomenon, although not 
completely understood, may involve dysregulation 
of mechanisms of neuroendothelial control and the 
presence of intravascular anomalies such as platelet 
activation, reduced fibrinolysis, activation of white 
blood cells, reduced deformability of red blood cells, 
high oxidative stress due to accumulation of free 
radicals and the possible presence of anti-endothelium 
antibodies25. In particular, platelet activation plays 
a key role in the natural history of the disease. 
Indeed, during systemic sclerosis, the α-granules of 
platelets release greater quantities of mediators with 
pleiotropic activities able to influence the natural 
history of the disease in various ways because 
they act on vascular tone and pro-inflammatory 
mechanisms as well as stimulating fibrogenesis and 
angiogenesis. In particular, high levels of vascular 
endothelial growth factor (VEGF) have been found 
in the serum of patients with systemic sclerosis. This 
growth factor, besides being involved in endothelial 
cell regeneration (stimulating their survival, growth, 
permeability and migration) is also involved in the 
regulation of inflammatory processes. The angiogenic 
activity and stabilisation of the vessel wall carried out 
by VEGF are expressed through interacvtions with 
other mediators present in the endothelium such as 
platelet-derived growth factor, transforming growth 
factor-β and angiopoietin26. Between 1966 al 2010, 
16 cases of systemic sclerosis associated with TTP 
were reported in the literature, one of which in a 
pregnant woman27-40; although the pathophysiological 
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mechanism underlying this association is not known, 
based on the foregoing, it can be hypothesised that the 
platelet activation present in systemic sclerosis could 
be a valid substrate for exposing a latent thrombotic 
state related to a functional or quantitative lack of 
ADAMTS13; furthermore, the presence of IgG 
autoantibodies against ADAMTS1314 is indicative 
of a relationship with autoimmune diseases, of which 
systemic sclerosis is one. 
The last case observed (case 4) focused our 
attention on the association between TTP and 
pregnancy. The incidence of pregnancy-associated 
TTP is 1:25,000 pregnancies and this form of TTP 
accounts for about 10% of all cases of TTP. The 
disease can appear de novo during the pregnancy or 
as a reactivation of a previously known TTP triggered 
by the pregnancy because of the presence of placental 
proteins in the bloodstream capable of inducing 
the production of anti-ADAMTS13 antibodies41. 
Unfortunately, these clinical pictures often overlap 
with pre-eclampsia/eclampsia and HELLP and so 
the diagnosis is missed. From a careful review of 
published data on pregnancy-associated TTP (from 
which cases of pre-eclampsia/eclampsia and HELLP 
were excluded) from 1955 to 2006, Martin et al. 
showed that the mean gestational age of onset of TTP 
is late: among the patients affected by ante-partum 
TTP, 55.5% developed the disorder in the second 
trimester of pregnancy (28.9±8.3 weeks), 32.8% 
during the third trimester (38.5±1.9 weeks) and only 
11.7% in the first trimester. TTP in the puerperium is 
less common (12.7%) and occurs a mean of 4 days 
after delivery, although the range is from 0 to 42 days. 
However, there are no significant differences in the 
outcome of patients who develop TTP ante-partum 
or post-partum with regards to either laboratory 
findings or maternal mortality (ante-partum 25.8%, 
post-partum 23.8%)42 and in both cases PEX (better 
if associated with adjuvant cortisone therapy) is the 
treatment of choice (Figure 4).
The type of response in the days immediately 
following suspension of PEX can be evaluated 
in the light of the cases observed. Patients with a 
first episode of disease are defined "responders" 
if they achieve normalisation of platelet count 
(≥150x109/L) and LDH (≤300 IU/L), an increase 
in haemoglobin (≥9.5 g/dL) and clinical resolution 
of neurological symptoms (when present) and 
signs of microangiopathy (ecchymoses, petechiae, 
haematomas) 3 days after the last treatment; 
as "partial responders" if they have a clear 
improvement in clinical and laboratory findings but 
a platelet count between 75x109/L and 150x109/L; 
and as "non-responders or refractory" if the 
platelet count remains ≤75x109/L with or without 
neurological disturbances and/or persistence of signs 
of microangiopathic damage. The patient with a 
relapse of TTP was evaluated using the same criteria 
but extending the time of observation to 8 days 
after the last treatment in order to assess whether 
a relapse occurred after suspension of treatment 
(Figures 5 and 6). 
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Figure 5 - Mean trends in laboratory parameters - mean platelet count (Plt), mean 
lactate dehydrogenase concentration (LDH) and mean haemoglobin 
concentration (Hb) - in patients responding to treatment (plasma 
exchange sessions in the box).
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In only two patients (cases 1 and 2) thrombocytopenia 
returned brusquely, after significant increases in 
platelet counts (reaching values ≥200x109/L) during 
PEX treatment, such that the counts fell again to 
values considerably below those established as the 
cut-of for defining non- responders. 
As mentioned, the underlying causes of these 
decreases in platelet count differed in the two patients. 
In case 1, after the first 7 days in which the platelet 
count was stable, the count began to decrease rapidly 
probably due to an early relapse of the disease. During 
this period the patient started treatment with rituximab 
(on day 26) which produced a slow recovery of the 
platelet count and level of haemoglobin (Figure 7). In 
contrast, case 2 showed an abrupt drop in circulating 
platelet count already during the last sessions of 
PEX contemporaneously with a brusque, fast rise 
in ALT due to CMV-associated hepatitis (Figure 
2). In reality, this patient, rather than being a true 
non-responder, should be considered to have had a 
complicated form of TTP in which the normalisation 
of the platelet count occurred not only in response to 
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Figure 7 - Trends in platelet count (Plt), lactate dehydrogenase concentration (LDH) 
and haemoglobin concentration (Hb) in a patient with a relapse of TTP 
not responding to treatment (plasma exchange sessions in the box) (case 
1). There is clear drop in the platelet count a few days after suspension of 
treatment and a persistently low count until the patient's discharge from 
hospital.
Figure 6 - Mean trends in laboratory parameters - mean platelet count (Plt), mean 
lactate dehydrogenase concentration (LDH) and mean haemoglobin 
concentration (Hb) - in patients not responding to treatment (plasma 
exchange sessions in the box). There is a clear drop in platelet count 
immediately after suspension of the treatment.
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the administration of rituximab (on day 17) but also 
because of the subsequent introduction of antiviral 
therapy (valaciclovir hydrochloride administered on 
day 23) (Figure 8).
The possibility of classifying the patients' outcome 
as a complete response or relapse will depend on their 
clinical wellbeing and laboratory results in a follow-
up lasting at least 12 months.
One further consideration should be made 
concerning the patients' blood groups. In recent 
studies on the correlation between TTP and blood 
group43 it has been seen that group O patients are 
underrepresented among patients with TTP, leading 
to the hypothesis that such individuals are partially 
protected against the development of TTP. This 
hypothesis is based on various observations made 
during comparisons of O group and non-O group 
individuals: subjects with blood group O have lower 
levels of VWF, faster clearance of VWF, faster 
proteolysis of VWF by ADAMTS13 and an inverse 
relationship between levels of plasma activity of 
ADAMTS13 and VWF. All these factors make group 
O subjects better protected against the development of 
TTP because they have less VWF available (the key 
protein in the aetiopathogenesis of TTP) and what is 
present is broken down more quickly. This protection 
from TTP is in line with previous observations that 
group O individuals have a degree of protection 
from myocardial, cerebral and peripheral vascular 
thrombosis44.
Terrel et al.45, who studied a larger cohort of 
patients (281 cases of TTP from 1995 to 2009 recruited 
through the Oklahoma TTP Registry) relating blood 
group with circulating ADAMTS13 levels, showed 
that in actual fact when there was a severe deficiency 
of ADAMTS 13, the frequency of blood group O was 
significantly higher than expected, whereas when 
the reduction of ADAMTS 13 was not severe, the 
frequency of group O individuals was lower than 
that of subjects with non-O groups (as previously 
found). The blood group characteristics are, therefore, 
probably only significant if ADAMTS13 function is 
not severely compromised.
The series of patients we studied was very small 
and did not allow us to make hypotheses on statistically 
significant correlations with the ABO system since 
quantitative, qualitative and genetic assays of the 
ADAMTS 13 profile were not conducted. However, 
we note that 75% of our patients had a non-O 
blood group and the only patient with group O was 
treated for TTP in relapse, an indicator of greater 
aggressiveness of the disease. This observation is in 
line with the previous considerations.
Conclusions
TTP, which is characterised by thrombocytopenia 
and microangiopathic haemolytic anaemia, was a fatal 
condition until the introduction, in 1970, of PEX, a 
treatment which has radically changed the natural 
history of this disease, reducing the mortality from 
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Figure 8 - Trends in platelet count (Plt), lactate dehydrogenase concentration (LDH) 
and haemoglobin concentration (Hb) in a patient with cytomegalovirus-
associated hepatitis and TTP not responding to treatment (plasma exchange 
sessions in the box) (case 2). The platelet count fell during treatment and 
returned to optimal levels after successful antiviral therapy.
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more than 90% to about 10-20%12. The mainstay of the 
treatment of acute TTP is daily PEX, exchanging the 
patient's plasma with fresh-frozen plasma or plasma 
lacking cryoprecipitate, which should be started 
within 24-48 hours of the appearance of the disease 
because it has been shown that a delay in initiation 
of therapy could be one of the factors responsible 
for treatment failure4. The duration of treatment 
required to obtain a remission varies greatly: the 
mean number of sessions necessary is about nine, 
since premature suspension or a single session of 
PEX can be associated with an exacerbation of the 
disease4. Furthermore, it is empirically recommended 
that exchange treatment is continued for at least 2 
days after the achievement of complete remission, 
in accordance with guidelines that call for treatment 
continuation until platelet counts reach values 
≥150x109/L and the levels of LDH return to within 
the normal range for 2-3 consecutive days. However, 
LDH, which is rapidly removed during PEX, does not 
reflect the response to treatment and even the possible 
persistence of some schistocytes in the peripheral 
blood smear, in the absence of other clinical and 
laboratory features, is not a contraindication to 
treatment suspension4. The guidelines of the American 
Society of Apheresis propose daily PEX treatment 
in TTP with a grade 1A recommendation (strong 
recommendation, high-quality evidence)15.
The value of plasma therapy was already 
demonstrated some years ago in a prospective, 
randomised trial comparing PEX and plasma infusions 
in the treatment of adults with TTP46: the 6-month 
survival rate was 78% in the group treated with 
PEX and 63% in that given plasma infusions, with 
this difference in favour of PEX being statistically 
significant (p=0.036). Nowadays the standard 
treatment for TTP is PEX with fresh-frozen plasma 
at a dose of 40 to 60 mL/Kg daily, started within 24 
hours of the diagnosis of the disease and continued 
for at least 2 days after the complete remission in 
which the patient achieves a normal platelet count and 
LDH level in the absence of neurological symptoms. 
Only in the case that PEX cannot be performed is 
treatment with plasma infusions indicated: the dose of 
the fresh-frozen plasma infusion is at least 30 mL/Kg 
daily4. In secondary forms, patients who are refractory 
to PEX and relapse are candidates for second-level 
therapy with splenectomy, vincristine, azathioprine 
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and also rational use of immunosuppressant drugs 
(corticosteroids, cyclophosphamide and cyclosporine) 
but above all with rituximab, a monoclonal chimeric 
antibody directed against CD20 (expressed on the 
surface of B lymphocytes), which rapidly depletes 
blood, lymph nodes and bone marrow of B cells. The 
rationale for using this drug in the treatment of TTP 
is its capacity to destroy the CD20+ B lymphocytes 
which produce anti-ADAMTS13 antibodies even if, 
in autoimmune diseases, the mechanism of action is 
not limited to depletion of B cells, as demonstrated 
by recent clinical studies in which the levels of 
autoantibodies were not significantly reduced during 
the treatment. In addition to the direct effect of the 
drug on B lymphocytes (depletion and consequent 
reduced function of cells presenting the antigen, 
release of inflammatory and immunomodulatory 
cytokines and co-stimulation signals), it has been 
proposed that the bond between rituximab and 
opsonised B cells blocks the function of the Fc 
receptor of macrophages. This block is able to reduce 
the splenic sequestration of platelets in TTP13,47,48.
More recently another drug, defibrotide, has 
acquired growing importance. This single-stranded 
polydeoxyribonucleotide derived from porcine 
mucosa (by controlled depolymerisation) has potent 
antithrombotic, anti-ischaemic and anti-inflammatory 
effects with thrombolytic properties without systemic 
anticoagulant effects. Defibrotide interacts with the 
receptor for adenosine and leads to the selective 
release of prostaglandins I2 and E2 with consequent 
inhibition of platelet function and activation, reduces 
the activity of plasminogen activator inhibitor-1 
and potentiates the function of tissue plasminogen 
activator49,50.
Patients with idiopathic TTP generally respond 
better to treatment with PEX than do patients with 
secondary TTP.
Keywords: thrombotic thrombocytopenic 
purpura, ADAMTS 13, plasma exchange therapy.
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